Literature DB >> 7907454

Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy.

K Alhainen1, P J Riekkinen.   

Abstract

We have studied whether it is possible to discriminate responders to tacrine treatment from patients nonresponsive to tacrine in Alzheimer's disease. The results indicate that mildly demented patients will most likely gain a benefit of tacrine treatment. Neuropsychological tests on attention and working memory after a single dose of tacrine might be useful as well as a single dose pharmaco-EEG in discriminating responders to treatment.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7907454     DOI： 10.1111/j.1600-0404.1993.tb04248.x

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN： 0065-1427


  12 in total

Review 1.  Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease.

Authors:  M Simard; R van Reekum
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

Review 2.  The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.

Authors:  A D Lawrence; B J Sahakian
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

3.  Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease.

Authors:  Davide V Moretti
Journal:  Am J Neurodegener Dis       Date:  2014-09-06

Review 4.  Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.

Authors:  Harald Hampel; Nicola Toschi; Claudio Babiloni; Filippo Baldacci; Keith L Black; Arun L W Bokde; René S Bun; Francesco Cacciola; Enrica Cavedo; Patrizia A Chiesa; Olivier Colliot; Cristina-Maria Coman; Bruno Dubois; Andrea Duggento; Stanley Durrleman; Maria-Teresa Ferretti; Nathalie George; Remy Genthon; Marie-Odile Habert; Karl Herholz; Yosef Koronyo; Maya Koronyo-Hamaoui; Foudil Lamari; Todd Langevin; Stéphane Lehéricy; Jean Lorenceau; Christian Neri; Robert Nisticò; Francis Nyasse-Messene; Craig Ritchie; Simone Rossi; Emiliano Santarnecchi; Olaf Sporns; Steven R Verdooner; Andrea Vergallo; Nicolas Villain; Erfan Younesi; Francesco Garaci; Simone Lista
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 5.  Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.

Authors:  Krista L Lanctôt; Nathan Herrmann; Maysoon M LouLou
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

6.  Neurophysiological predictors of long term response to AChE inhibitors in AD patients.

Authors:  V Di Lazzaro; A Oliviero; F Pilato; E Saturno; M Dileone; C Marra; S Ghirlanda; F Ranieri; G Gainotti; P Tonali
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

Review 7.  A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease.

Authors:  S C Samuels; K L Davis
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.228

Review 8.  Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease.

Authors:  A J Wagstaff; D McTavish
Journal:  Drugs Aging       Date:  1994-06       Impact factor: 3.923

Review 9.  Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel.

Authors:  Claudio Babiloni; Xianghong Arakaki; Hamed Azami; Karim Bennys; Katarzyna Blinowska; Laura Bonanni; Ana Bujan; Maria C Carrillo; Andrzej Cichocki; Jaisalmer de Frutos-Lucas; Claudio Del Percio; Bruno Dubois; Rebecca Edelmayer; Gary Egan; Stephane Epelbaum; Javier Escudero; Alan Evans; Francesca Farina; Keith Fargo; Alberto Fernández; Raffaele Ferri; Giovanni Frisoni; Harald Hampel; Michael G Harrington; Vesna Jelic; Jaeseung Jeong; Yang Jiang; Maciej Kaminski; Voyko Kavcic; Kerry Kilborn; Sanjeev Kumar; Alice Lam; Lew Lim; Roberta Lizio; David Lopez; Susanna Lopez; Brendan Lucey; Fernando Maestú; William J McGeown; Ian McKeith; Davide Vito Moretti; Flavio Nobili; Giuseppe Noce; John Olichney; Marco Onofrj; Ricardo Osorio; Mario Parra-Rodriguez; Tarek Rajji; Petra Ritter; Andrea Soricelli; Fabrizio Stocchi; Ioannis Tarnanas; John Paul Taylor; Stefan Teipel; Federico Tucci; Mitchell Valdes-Sosa; Pedro Valdes-Sosa; Marco Weiergräber; Gorsev Yener; Bahar Guntekin
Journal:  Alzheimers Dement       Date:  2021-04-15       Impact factor: 16.655

10.  Spectral Analysis of EEG in Familial Alzheimer's Disease with E280A Presenilin-1 Mutation Gene.

Authors:  Rene Rodriguez; Francisco Lopera; Alfredo Alvarez; Yuriem Fernandez; Lidice Galan; Yakeel Quiroz; Maria Antonieta Bobes
Journal:  Int J Alzheimers Dis       Date:  2014-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.